Vaxxinity, Inc. (VAXX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerVaxxinity, Inc. (VAXX) trades at $0.0001. Vaxxinity, Inc. is a biotechnology company focused on developing immunotherapeutic vaccines for chronic diseases. Their pipeline targets Alzheimer's, Parkinson's, migraines, and cardiovascular disease, along with a COVID-19 vaccine. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for VAXX: VAXX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Vaxxinity, Inc. (VAXX) Healthcare & Pipeline Overview
Vaxxinity, Inc. is a biotechnology company developing immunotherapeutic vaccines targeting major chronic diseases such as Alzheimer's and Parkinson's, alongside cardiovascular and migraine treatments, and a COVID-19 vaccine. Their focus on innovative vaccine technology positions them within the competitive biotechnology landscape, addressing significant unmet medical needs.
What Is the Investment Thesis for VAXX?
Vaxxinity's investment thesis hinges on the successful development and commercialization of its innovative immunotherapeutic vaccines. The company's focus on chronic diseases with large patient populations presents significant market opportunities. Key value drivers include the progression of UB-311 through Phase 2 trials for Alzheimer's disease, with potential for breakthrough therapy designation and accelerated approval. Positive Phase 1 results for UB-312 in Parkinson's disease could also drive investor interest. The Phase 3 trial results for UB-612, the COVID-19 vaccine, are a near-term catalyst. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established pharmaceutical companies. With a market cap of $0.00B and a P/E ratio of -0.22, Vaxxinity is a high-risk, high-reward investment opportunity.
Based on FMP financials and quantitative analysis
VAXX Key Highlights
UB-311 is in Phase 2 clinical trials targeting Alzheimer's disease, a market with significant unmet needs.
- UB-312 is in Phase 1 clinical trials for Parkinson's disease and other synucleinopathies.
- UB-612, a COVID-19 vaccine, is in Phase 3 clinical trials, representing a near-term potential revenue stream.
- The company's anti-PCSK9 vaccine targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events.
- Vaxxinity's innovative vaccine platform aims to stimulate the body's own immune system to fight against disease-causing proteins.
Who Are VAXX's Competitors?
VAXX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | — |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | — |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VAXX's Key Strengths?
Innovative vaccine platform technology.
- Diverse pipeline of vaccine candidates targeting major chronic diseases.
- Experienced management team with expertise in vaccine development.
- Phase 2 clinical trial underway for Alzheimer's disease vaccine.
What Are VAXX's Weaknesses?
Limited financial resources.
- High dependence on clinical trial outcomes.
- Lack of commercialized products.
- OTC market listing.
What Are the Key Risks for VAXX?
Financial-distress signal — its Altman Z-Score of -15.19 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-0.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could significantly impact the company's valuation.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from established pharmaceutical companies with greater resources.
- Limited financial resources and dependence on external funding.
- Risks associated with operating on the OTC market.
What Are VAXX's Competitive Advantages?
- Proprietary vaccine platform technology.
- Patent protection for its vaccine candidates.
- Clinical data demonstrating safety and efficacy.
- Expertise in immunotherapeutic vaccine development.
What Does VAXX Do?
Founded in 2014 and headquartered in Dallas, Texas, Vaxxinity, Inc. is a biotechnology company dedicated to developing novel immunotherapeutic vaccines aimed at combating chronic diseases. The company's core strategy revolves around its innovative vaccine platform designed to stimulate the body's own immune system to fight against disease-causing proteins. Vaxxinity's pipeline includes product candidates targeting some of the most prevalent and debilitating conditions, including Alzheimer's disease (AD), Parkinson's disease, migraines, and cardiovascular disease. Their lead product candidate, UB-311, is currently in Phase 2 clinical trials for Alzheimer's disease, targeting toxic forms of aggregated amyloid-beta in the brain. UB-312, in Phase 1, aims to address Parkinson's disease and other synucleinopathies by targeting aggregated alpha-synuclein. Additional programs include UB-313 for migraines, an anti-PCSK9 vaccine for cardiovascular disease, and UB-612, a COVID-19 vaccine in Phase 3 trials. Vaxxinity is working to establish itself as a leader in the field of immunotherapeutic vaccines, addressing significant unmet needs in neurology and other chronic diseases.
What Products and Services Does VAXX Offer?
- Develop immunotherapeutic vaccines for chronic diseases.
- Target Alzheimer's disease with UB-311, currently in Phase 2 clinical trials.
- Target Parkinson's disease and other synucleinopathies with UB-312, currently in Phase 1 clinical trials.
- Develop UB-313 for the treatment of migraines.
- Develop an anti-PCSK9 vaccine to lower LDL cholesterol and reduce the risk of cardiac events.
- Develop UB-612 for neutralizing the SARS-CoV-2 virus, currently in Phase 3 clinical trials.
How Does VAXX Make Money?
- Develop and patent novel immunotherapeutic vaccines.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Partner with pharmaceutical companies for commercialization or commercialize products independently.
What Industry Does VAXX Operate In?
Vaxxinity operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The COVID-19 vaccine market remains substantial, although increasingly competitive. Vaxxinity's success depends on its ability to differentiate its vaccine platform and navigate the complex regulatory landscape. Competitors include both large pharmaceutical companies and smaller biotech firms focused on similar therapeutic areas.
Who Are VAXX's Key Customers?
- Patients suffering from Alzheimer's disease, Parkinson's disease, migraines, and cardiovascular disease.
- Healthcare providers who prescribe and administer vaccines.
- Pharmaceutical companies that may license or acquire Vaxxinity's products.
- Government agencies and public health organizations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Vaxxinity, Inc. stands at -0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.1%, showing how much profit it generates from its asset base. A current ratio of 1.89 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Vaxxinity, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Merritt Island, US. The company is led by CEO Mei Mei Hu. VAXX has traded publicly since 2021.
Financial Health
Vaxxinity, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.19 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Vaxxinity, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 14.5% above estimates on average.
Forward Outlook
Wall Street analysts project Vaxxinity, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.41.
Insider Activity
12 transactions · 0 purchases, 10 sales, 2 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
VAXX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
VAXX Latest News
No recent news available for VAXX.
VAXX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VAXX.
Price Targets
Wall Street price target analysis for VAXX.
VAXX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VAXX; grades run from A+ (80-100) to F (below 30).
Leadership: Mei Mei Hu
CEO
Mei Mei Hu serves as the CEO of Vaxxinity, bringing extensive experience in the pharmaceutical and biotechnology industries. Prior to Vaxxinity, she held leadership positions at COVAXX and United Biomedical, Inc. Ms. Hu has a strong background in strategic planning, business development, and commercialization. She has a track record of driving growth and innovation in the healthcare sector. Her experience includes overseeing clinical trials, securing regulatory approvals, and building strategic partnerships.
Track Record: Under Mei Mei Hu's leadership, Vaxxinity has advanced its pipeline of vaccine candidates, including UB-311 into Phase 2 clinical trials for Alzheimer's disease. She has also overseen the development of UB-312 for Parkinson's disease and UB-612 for COVID-19. Her strategic focus has been on leveraging Vaxxinity's innovative vaccine platform to address unmet medical needs in chronic diseases.
VAXX OTC Market Information
The OTC Other tier, also known as the Pink Market, represents the lowest tier of the OTC market. Companies on this tier often have limited financial disclosure, may be distressed, or may not meet the minimum requirements for higher tiers like OTCQB or OTCQX. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. Companies in this tier are not required to meet minimum financial standards and may not be current in their reporting.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of fraud and misrepresentation.
- Low liquidity makes it difficult to buy or sell shares.
- Lack of regulatory oversight increases the risk of price manipulation.
- Companies on the OTC Other tier may be financially distressed or have a history of regulatory violations.
- Higher volatility compared to stocks listed on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's legal and regulatory history.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Experienced management team with a track record in the biotechnology industry.
- Pipeline of vaccine candidates targeting major chronic diseases.
- Ongoing clinical trials for key vaccine candidates.
- Focus on addressing unmet medical needs.
- Scientific publications or presentations supporting the company's technology.
What Investors Ask About Vaxxinity, Inc. (VAXX) — Healthcare
What do analysts say about VAXX stock?
As of March 16, 2026, there is no readily available analyst consensus on VAXX stock due to its OTC listing and limited coverage. Key valuation metrics such as price-to-earnings (P/E) ratio are not meaningful due to negative earnings.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.